HHS adds Duchenne muscular dystrophy to recommended screening panel

Department of Health and Human Services Secretary Robert F. Kennedy approved the addition of Duchenne muscular dystrophy and metachromatic leukodystrophy to the recommended uniform screening panel following scientific review and public comment. “Early detection of both conditions allows children to receive FDA-approved therapies at the most effective time, helping to slow disease progression and preserve their quality of life,” the agency said in a statement. Companies with Duchenne muscular dystrophy treatments include Sarepta (SRPT), Solid Biosciences (SLDB). Shares of Sarepta moved higher following the announcement.